Next-generation IPL arrives

April 11, 2022 Staff reporters

Launched during RANZCO’s virtual congress, Quantel Medical’s C.Stim offers new intense pulsed light (IPL) technology for the treatment of the root causes of dry eye: meibomian gland dysfunction, inflammation and Demodex.


“Drawing on Quantel Medical’s years of experience in intense pulsed light in dermatology, we have now developed a new IPL device exclusively for use in ophthalmology, designed and manufactured by the Lumibird Medical Group," said Jean-Marc Gendre, CEO of Lumibird Medical. "We are convinced that this new premium product will bring an innovative therapeutic solution to ophthalmologists confronted with the daily challenge of dry eye treatment.”


C.Stim combines cutting-edge technology with a sleek, robust and ergonomic design, said Quantel Medical’s dry eye product manager Delphine Southon. “Thanks to its unique Stim-ULI (uniform light intensity) technology, C.Stim offers the best combination of clinical efficacy and patient comfort.”


New Zealand distributor, Titan Health’s Campbell Gordon, says it’s this technology that sets this device apart. “Stim-ULI technology delivers a more uniform pulsed light. This allows it to operate at a lower energy range and in turn is more comfortable for patients as it doesn’t have a concentrated hot spot right in the middle. So the treatment energy will be more uniformly delivered across the patient’s face. (Compared to) other units, the C.Stim handpiece and flash also has a longer lifespan before it needs to be changed.”


C.Stim is available for pre-ordering in New Zealand now, said Gordon.